by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 1st, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »September 1st, 2017: “EURETINA-Brief”© Issue No. 160
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their experimental GS010 treatment for LHON has completed enrollment in the company’s Phase III clinical… Read More »GenSight Biologics Inc. reports completion of Phase III enrolment for a gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their experimental GS010 treatment for LHON has completed enrollment in the company’s Phase III clinical… Read More »GenSight Biologics Inc. reports completion of Phase III enrolment for a gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
The Clinical Research Institute (CRI) of the Foundation Fighting Blindness (FFB) has announced the enrollment of the first patient in a 4-year study to delineate… Read More »International clinical study, supported by Foundation Fighting Blindness, aims to establish the natural history of Usher syndrome type 2A
A joint Spanish and Israeli study, conducted by investigators from the Fundacion Jimenez Diaz University Hospital (IIS-FJD, UAM), Madrid, and the Israel Institute of Technology… Read More »Joint Spanish and Israeli research identifies recessive gene mutations underlying syndromic RP and intellectual disability
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 18th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 18th, 2017: “EURETINA-Brief”© Issue No. 159
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced the submission of a Marketing Authorization Application (MAA) to the European Medicines… Read More »Spark Therapeutics files marketing authorization application at EMA for the treatment of Leber’s congenital amaurosis (LCA)
Results from a Phase II multicentre randomised trial, which had enrolled 67 patients, with macular telangiectasia 2, has reported meeting its primary endpoint, defined as… Read More »Phase II results from encapsulated cell therapy technology show benefit in the treatment of patients with macular telangiectasia 2
A US study, published in the journal Nature (Aug 3rd, 2017), has shown that a regenerative gene from zebrafish is capable of driving the generation… Read More »Reprogramming of Müller glia cells in mammalian retina promotes regeneration of neuronal cells following injury
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 4th, 2017: “EURETINA-Brief”© Issue No. 158.